Copaxone Recent News
Mylan And Teva And Copaxone, Explained
Mylan's Generic Copaxone Arrives, Teva Sales To Take A Hit
Why Is Teva Falling? Competition
What Approval For Generic Copaxone Means For Mylan
Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva
The Prescription For Generic Drugs ETF
Teva Downgraded As Analyst Casts Doubt On Turnaround Story
Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated
It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date
Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
Citi Weighs In On The 'Turmoil At Teva'
A District Court's Ruling Against Teva Pharma Opens The Door For Generics
What The Copaxone Court Ruling Means For Teva Pharmaceuticals
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision
Jefferies Warns Of 'Too Many Headwinds' For Teva
Teva Pharmaceuticals Could Be Poised For A Turnaround
Synthetic Biologics Crashes Following Disappointing Phase 2 Results
Momenta Pharmaceuticals Spikes Up Following FDA News On Copaxone
Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks
Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic Competition
Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss
Market Wrap For May 1: Markets Mixed To Start The New Month